コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ithout spontaneous breathing (prevented by a neuromuscular blocking agent).
2 nts all had ARDS and had been treated with a neuromuscular blocking agent.
3 he adverse events associated with the use of neuromuscular blocking agents.
4 ght complexes in a 1: 1 ratio with steroidal neuromuscular blocking agents.
5 al, many monitors are affected by the use of neuromuscular blocking agents.
6 igned that selectively encapsulate steroidal neuromuscular blocking agents.
7 ects of combining different non-depolarizing neuromuscular blocking agents.
8 eroids in combination with variable doses of neuromuscular blocking agents.
9 ined after discontinuation of treatment with neuromuscular blocking agents.
10 unintended extubation in patients receiving neuromuscular-blocking agents.
11 in patients receiving continuous infusion of neuromuscular-blocking agents.
12 of less than 180 mg/dL in patients receiving neuromuscular-blocking agents.
13 specific to patients receiving infusions of neuromuscular-blocking agents.
14 sedation during continuous administration of neuromuscular-blocking agents.
15 in patients with myasthenia gravis receiving neuromuscular-blocking agents.
16 r patients receiving continuous infusions of neuromuscular-blocking agents.
18 s that a protocol should include guidance on neuromuscular-blocking agent administration in patients
19 xamined the association between receipt of a neuromuscular blocking agent and in-hospital mortality a
21 e-Dawley rats (age 4 months), treated with a neuromuscular blocking agent and ventilated: control, hy
23 Long-term treatment with nondepolarizing neuromuscular blocking agents and corticosteroids in the
26 alysis suggests a modest association between neuromuscular blocking agents and neuromuscular dysfunct
27 ed trial did not show an association between neuromuscular blocking agents and neuromuscular dysfunct
28 ndromes were also associated with the use of neuromuscular blocking agents and prolonged mechanical v
29 f an adverse relationship between the use of neuromuscular blocking agents and skeletal muscle weakne
32 d guidelines and protocols could ensure that neuromuscular blocking agents are used and monitored app
33 an instrumental variable found receipt of a neuromuscular blocking agent associated with a 4.3% (95%
34 studied the ability of four nondepolarizing neuromuscular blocking agents (atracurium, gallamine, me
36 practice suggests that a reduced dose of an neuromuscular-blocking agent be used for patients with m
38 6) Optimal clinical practice suggests that neuromuscular-blocking agents be discontinued prior to t
40 romuscular weakness and included charges for neuromuscular blocking agents, continuous mechanical ven
41 sistent weight over another when calculating neuromuscular-blocking agent doses in obese patients.
42 ht or adjusted body weight) when calculating neuromuscular-blocking agents doses for obese patients.
45 make no recommendation on the routine use of neuromuscular-blocking agents for patients undergoing th
46 s, 'experts' in the clinical pharmacology of neuromuscular blocking agents have advocated routine int
47 predominant one, along with potentiation by neuromuscular blocking agents, immobilization, and proba
52 She is placed in the prone position and a neuromuscular blocking agent is administered, without im
53 espiratory infection, early treatment with a neuromuscular blocking agent is associated with lower in
55 Recent trials suggest that treatment with neuromuscular blocking agents may improve survival in pa
56 nsible for ICU-AW and provides evidence that neuromuscular blocking agents may not be a major cause o
58 suggested that some pairs of nondepolarizing neuromuscular blocking agents might be more efficacious
59 er that irrespective of chemical structural, neuromuscular blocking agents might produce prolonged pa
60 modynamic monitoring and use of sedative and neuromuscular blocking agents, more mechanical ventilati
61 guidelines during use of continuous-infusion neuromuscular blocking agents (NMB) in the intensive car
62 pertoire [10/44 (23%) lacked BSACI compliant neuromuscular blocking agent (NMBA) panels and 17/44 (39
66 e administration of analgesic, sedative, and neuromuscular blocking agents (NMBAs) for each patient.
71 prescriptions of sedative, analgesic, and/or neuromuscular blocking agents; nurse administration of t
72 o significantly more likely to have received neuromuscular blocking agents (p = .004) or propofol (p
73 requirements for vasopressors, sedatives, or neuromuscular blocking agents, percentage of patients th
75 ered one or more sedative, analgesic, and/or neuromuscular blocking agent, range 1-9 drugs, mean 2.5
76 patients receiving a continuous infusion of neuromuscular-blocking agent receive a structured physio
77 neuromuscular blockade: encapsulation of the neuromuscular blocking agent, resulting in inactivation.
78 groups bind tightly to several commonly used neuromuscular blocking agents, such as rocuronium, in aq
80 his system have the capability to administer neuromuscular blocking agents to facilitate intubation (
81 est against the routine administration of an neuromuscular-blocking agents to mechanically ventilated
83 ted data included demographics, sedation and neuromuscular blocking agents used, mechanical ventilati
84 e adult cats, anaesthetized, injected with a neuromuscular blocking agent, vagotomized and artificial
85 n the propensity for treatment, receipt of a neuromuscular blocking agent was associated with a reduc
88 nd route of administration for sedatives and neuromuscular blocking agents were abstracted from ICU f
92 ompare the outcomes of patients treated with neuromuscular blocking agents within the first 2 hospita
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。